| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Acquired in-process research and development | $0-100.0% | $3.8M | $0 | — | — | — | — |
| Research and development | $349K-88.9% | $3.2M-86.9% | $24.1M-22.2% | $31.0M-40.8% | $52.4M-4.4% | $54.8M+29.6% | $42.3M |
| General and administrative | $5.7M-48.3% | $11.0M-51.8% | $22.8M+13.0% | $20.2M-3.5% | $21.0M+33.4% | $15.7M+87.9% | $8.4M |
| Write-off of acquired intangible asset | $0-100.0% | $2.3M | $0 | — | — | — | — |
| Write-off of goodwill | $0-100.0% | $881K | $0 | — | — | — | — |
| Gain on litigation settlement | $0+100.0% | -$975K | $0 | — | — | — | — |
| Loss from operations | -$2.5M+87.4% | -$20.2M+59.1% | -$49.3M+3.8% | -$51.2M+30.2% | -$73.4M-4.0% | -$70.6M-39.2% | -$50.7M |
| Interest income | $248K-55.2% | $554K-65.3% | $1.6M+215.2% | $506K+1481.3% | $32K-97.3% | $1.2M-35.6% | $1.8M |
| Gain on extinguishment of debt | $151.0M | $0 | — | — | — | — | — |
| Gain on sale of dismutase mimetics assets | -$3.5M | $0 | — | — | — | — | — |
| Change in fair value of warrant liability | $294K-35.0% | $452K | $0 | — | — | — | — |
| Foreign currency loss | $0+100.0% | -$6K-100.0% | -$3K-200.0% | -$1K+75.0% | -$4K-116.0% | $25K+162.5% | -$40K |
| Income (loss) before income tax benefit | $149.0M+877.9% | -$19.2M+67.6% | -$59.1M+5.2% | -$62.3M+22.7% | -$80.5M-8.5% | -$74.2M-42.9% | -$51.9M |
| Income tax benefit | $0-100.0% | $203K | $0-100.0% | $70K | $0-100.0% | $16K+77.8% | $9K |
| Net income (loss) | $149.0M+886.2% | -$19.0M+67.9% | -$59.1M+5.0% | -$62.2M+22.7% | -$80.5M-8.5% | -$74.2M-42.9% | -$51.9M |
| Net income (loss) attributable to common stockholders, basic | $76.9M+34451.8% | -$224K+99.6% | -$59.1M | — | — | — | -$59.1M |
| Net income (loss) attributable to common stockholders, diluted | $76.9M+34451.8% | -$224K+99.6% | -$59.1M | — | — | — | — |
| Net income (loss) per share of common stock, basic | $644.89+288.1% | -$342.89-25681.2% | -$1.33 | — | — | — | — |
| Net income (loss) per share of common stock, diluted | $644.89+288.1% | -$342.89-25681.2% | -$1.33 | — | — | — | — |
| Weighted-average shares of common stock outstanding, basic | 119K+18200.3% | 652 | 0-100.0% | 27.09B | — | — | — |
| Weighted-average shares of common stock outstanding, diluted | 119K+18200.3% | 652 | 0-100.0% | 27.09B | — | — | — |
| Series B Redeemable Convertible Preferred Stockholders [Member] | |||||||
| Series B Redeemable Convertible Preferred Stock [Member] | |||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.